Chromocell Therapeutics Net Income

The latest net income for CHRO is $-72M as of June 2026. That compares with $-9M in the prior-year period — down 691.7% year over year. That is below the sector sector average of $87M. Investors often review this figure alongside Chromocell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CHRO's net income moved from $-9M to $-72M — a 691.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Chromocell Therapeutics's operating scale or balance-sheet position.

Against its sector companies, CHRO currently prints $-72M for net income, while the sector average sits near $87M. That is roughly 182.7% below the sector mean. Large gaps often invite a closer look at Chromocell Therapeutics's growth, margins, and balance sheet.

A net income figure of $-72M for CHRO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $87M. Explore the charts below for those layers of context.

After noting CHRO's net income ($-72M), review year-over-year change from $-9M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.